MedPageToday -- A novel insulin that releases over several days appears as effective as once-daily standard insulin in type 2 diabetes, an open-label trial found. Glycosylated hemoglobin levels reached a similar 7.2% to 7.5% over 16 weeks whether patients got the novel insulin degludec three times a week or once daily, or standard insulin glargine (Lantus) once daily, Bernard Zinman, MD, of Mount Sinai Hospital at the University of Toronto, and colleagues reported online in The Lancet.
